PRA Health Sciences (PRA Health Sciences) Debt-to-EBITDA : 3.19 (As of Mar. 2021)

View and export this data going back to 2014. Start your Free Trial

What is PRA Health Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PRA Health Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $155 Mil. PRA Health Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $1,303 Mil. PRA Health Sciences's annualized EBITDA for the quarter that ended in Mar. 2021 was $458 Mil. PRA Health Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 was 3.19.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PRA Health Sciences's Debt-to-EBITDA or its related term are showing as below:

PRAH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.77 Med: 3.64 Max: 7.71
Current: 3.26

During the past 9 years, the highest Debt-to-EBITDA Ratio of PRA Health Sciences was 7.71. The lowest was 2.77. And the median was 3.64.

PRAH's Debt-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 1.8 vs PRAH: 3.26

PRA Health Sciences Debt-to-EBITDA Historical Data

The historical data trend for PRA Health Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PRA Health Sciences Debt-to-EBITDA Chart

PRA Health Sciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-EBITDA

Get a 7-Day Free Trial

3.79

6.75

2.77

3.10

3.40

PRA Health Sciences Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Debt-to-EBITDA	Get a 7-Day Free Trial															3.63	5.71	2.50	3.16	3.19

Competitive Comparison of PRA Health Sciences's Debt-to-EBITDA

For the Diagnostics & Research subindustry, PRA Health Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PRA Health Sciences's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PRA Health Sciences's Debt-to-EBITDA falls into.

PRA Health Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PRA Health Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(155.931	+	1317.651)	/	433.769
	=	3.40

PRA Health Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(155.071	+	1303.214)	/	457.664
	=	3.19

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2021) EBITDA data.

PRA Health Sciences (NAS:PRAH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PRA Health Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PRA Health Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PRA Health Sciences (PRA Health Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PRA Health Sciences Inc (NAS:PRAH) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612

Website

https://www.prahs.com

PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.

Executives

Michael J. Bonello	officer: EVP & CFO	4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Shannon Colin	director, officer: President & CEO	PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190
Christopher L Gaenzle	officer: EVP, CAO & General Counsel	C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604
Glen D. Stettin	director	C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Alexander George Dickinson	director	31542 CATALINA AVE LAGUNA BEACH CA 92651
Jeffrey T Barber	director	6501 WESTON PARKWAY, SUITE 200 CARY NC 27513
Matthew P. Young	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
George R Roberts	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025
Kkr Pra Investors Gp Ii Llc	10 percent owner	9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors L.p.	10 percent owner	9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors Gp Llc	10 percent owner	9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr North America Xi Ltd	10 percent owner	KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Kkr North America Fund Xi L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001